Center-Authored Papers

Filters: Keyword is Leukemia, Myeloid, Chronic-Phase  [Clear All Filters]
Journal Article
Uberti JP, Agovi M-A, Tarima S, Haagenson M, Gandham S, Anasetti C, Baker KS, Bolwell BJ, Bornhauser M, Chan KW et al..  2011.  Comparative analysis of BU and CY versus CY and TBI in full intensity unrelated marrow donor transplantation for AML, CML and myelodysplasia.. Bone marrow transplantation. 46(1):34-43. Abstract
Kim DHD' ', Sriharsha L, Jung CW, Kamel-Reid S, Radich JP, Lipton JH.  2010.  Comprehensive evaluation of time-to-response parameter as a predictor of treatment failure following imatinib therapy in chronic phase chronic myeloid leukemia: which parameter at which time-point does matter? American journal of hematology. 85(11):856-62. Abstract
Hochhaus A, Müller MC, Radich JP, Branford S, Kantarjian HM, Hanfstein B, Rousselot P, Kim D-W, Lipton JH, Bleickardt E et al..  2009.  Dasatinib-associated major molecular responses in patients with chronic myeloid leukemia in chronic phase following imatinib failure: response dynamics and predictive value.. Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K. 23(9):1628-33. Abstract
Beer PA, Knapp DJHF, Miller PH, Kannan N, Sloma I, Heel K, Babovic S, Bulaeva E, Rabu G, Terry J et al..  2015.  Disruption of IKAROS activity in primitive chronic-phase CML cells mimics myeloid disease progression.. Blood. 125(3):504-15. Abstract
Cortes JE, Kantarjian HM, Goldberg SL, Powell BL, Giles FJ, Wetzler M, Akard L, Burke JM, Kerr R, Saleh M et al..  2009.  High-dose imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: high rates of rapid cytogenetic and molecular responses.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 27(28):4754-9. Abstract
Kantarjian HM, Giles FJ, Bhalla KN, Pinilla-Ibarz J, Larson RA, Gattermann N, Ottmann OG, Hochhaus A, Radich JP, Saglio G et al..  2011.  Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results.. Blood. 117(4):1141-5. Abstract